BioNTech SE (BNTX) reports a net profit for Q4 2024 amidst a challenging year, with strategic advancements in oncology and ...

BioNTech SE (Nasdaq: BNTX, “BioNTech” or “the Company”) will present data for selected assets from its diversified oncology pipeline, including mRNA cancer immunotherapies, next-generation ...

BioNTech SE(Nasdaq: BNTX, "BioNTech" or "the Company") will present data for selected assets from its diversified oncology pipeline, including mRNA cancer immunotherapies ...

In a report released today, Asthika Goonewardene from Truist Financial maintained a Buy rating on BioNTech SE (BNTX – Research Report). The ...

Morgan Stanley analyst Terence Flynn maintained a Buy rating on BioNTech SE (BNTX – Research Report) today and set a price target of $140.00.

BioNTech SE ( ($BNTX) ) has shared an update. On April 4, 2025, BioNTech SE announced the invitation to its Annual General Meeting scheduled for ...

BioNTech (BNTX) witnessed a jump in share price last session on above-average trading volume. The latest trend in earnings ...

BioNTech SE (NASDAQ:BNTX – Get Free Report) has received a consensus recommendation of “Moderate Buy” from the eighteen brokerages that are covering the company, MarketBeat.com reports.

Oncology experts discuss de-escalation strategies that can reduce toxicity, save a billion in healthcare costs, and make lung ...